Paris, France, April 15, 2026, 6:00 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its 2025 Universal Registration Document (URD) in English was filed with the French market authority (Autorités des Marchés Financiers, or AMF) on April 14, 2026, under the reference D.26-0251.

The Universal Registration Document includes in particular:

  • The 2025 annual financial report;
  • The management report;
  • The report on corporate governance; and
  • The description of the share buyback program.

The Universal Registration Document may be consulted on the Company’s website (www.gensight-biologics.com), “Investors” section, and on the AMF’s website (www.amf-france.org).

Contacts